Collegium Pharmaceutical (COLL) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 6.7% versus a loss of 34.3%. Over five years, COLL leads with a +4.5% price change compared with -52.6% for PCRX. Pacira BioSciences is the larger company by market cap ($1.00 billion vs $713.9 million), about 1.4 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 7.3x for Pacira BioSciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | PCRX |
|---|---|---|
| Share price | $21.93 | $25.20 |
| Market cap | $713.94M | $1.00B |
| 1-day change | +0.23% | +1.78% |
| YTD return | -52.63% | -2.63% |
| 1-year return | -34.32% | +6.69% |
| 5-year return | +4.53% | -52.63% |
| P/E ratio (TTM) | 17.27 | 72.00 |
| Forward P/E | 3.30 | 7.27 |
| EPS (TTM) | $1.27 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $27.66 |
| 52-week low | $21.43 | $18.80 |
| Distance from 52-week high | -56.82% | -8.89% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +123.44% | +19.48% |
| Average volume | 747.73K | 581.50K |
| Shares outstanding | 32.56M | 39.86M |
| Employees | 423 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed COLL by 41.0 percentage points over the past year.
- Pacira BioSciences trades at a higher earnings multiple (72.0x vs 17.3x trailing P/E).
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
COLL vs PCRX FAQ
Which is bigger, Collegium Pharmaceutical or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.00B compared with $713.94M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or PCRX?
PCRX returned +6.69% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COLL or PCRX?
COLL has the lower trailing P/E at 17.3, versus 72.0 for PCRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Collegium Pharmaceutical and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.